Synergistic cytotoxicity of perifosine and ABT-737 to colon cancer cells

Investor logo

Warning

This publication doesn't include Faculty of Arts. It includes Faculty of Science. Official publication website can be found on muni.cz.
Authors

ADAMOVÁ Barbora ŘÍHOVÁ Kamila POKLUDOVÁ Jana BENEŠ Petr ŠMARDA Jan NAVRÁTILOVÁ Jarmila

Year of publication 2023
Type Article in Periodical
Magazine / Source Journal of Cellular and Molecular Medicine
MU Faculty or unit

Faculty of Science

Citation
Web https://onlinelibrary.wiley.com/doi/10.1111/jcmm.17636
Doi http://dx.doi.org/10.1111/jcmm.17636
Keywords ABT-737; colon cancer; combined treatment; peeling analysis; perifosine; spheroids; synergism; tumour microenvironment
Attached files
Description An acidic environment and hypoxia within the tumour are hallmarks of cancer that contribute to cell resistance to therapy. Deregulation of the PI3K/Akt pathway is common in colon cancer. Numerous Akt-targeted therapies are being developed, the activity of Akt-inhibitors is, however, strongly pH-dependent. Combination therapy thus represents an opportunity to increase their efficacy. In this study, the cytotoxicity of the Akt inhibitor perifosine and the Bcl-2/Bcl-xL inhibitor ABT-737 was tested in colon cancer HT-29 and HCT-116 cells cultured in monolayer or in the form of spheroids. The efficacy of single drugs and their combination was analysed in different tumour-specific environments including acidosis and hypoxia using a series of viability assays. Changes in protein content and distribution were determined by immunoblotting and a “peeling analysis” of immunohistochemical signals. While the cytotoxicity of single agents was influenced by the tumour-specific microenvironment, perifosine and ABT-737 in combination synergistically induced apoptosis in cells cultured in both 2D and 3D independently on pH and oxygen level. Thus, the combined therapy of perifosine and ABT-737 could be considered as a potential treatment strategy for colon cancer.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.